Steven R. Goldstein, MD

News

Skilled US imaging of the adnexae: The non-neoplastic mass

Author:: Steven R. Goldstein, MD

Publish date: October 1, 2010

From simple cysts to endometriomas, nonneoplastic ovarian masses can be identified through ultrasonographic observation of their essential traits<...

News

Skilled US imaging of the adnexal mass: Starting point

Author:: Steven R. Goldstein, MD

Publish date: September 1, 2010

Whether you scan the patient yourself or refer her to an ultrasonography lab, you need to be able to identify both physiologic and pathologic stru...

News

OSTEOPOROSIS

Author:: Steven R. Goldstein, MD

Publish date: November 1, 2009

New data enhance our understanding of the effects of some contraceptives and key SERMs on the skeletal health of users

News

The case for chemoprevention as a tool to avert breast cancer

Author:: Steven R. Goldstein, MD

Publish date: July 1, 2009

Women at high risk of invasive breast cancer can elect chemoprevention with tamoxifen or raloxifene. An aromatase inhibitor may one day be an opti...

News

OSTEOPOROSIS

Author:: Steven R. Goldstein, MD

Publish date: November 1, 2008

News

OSTEOPOROSIS

Author:: Steven R. Goldstein, MD

Publish date: November 1, 2007

Recent data refine our understanding of how to use key drugs, particularly bisphosphonates, zoledronic acid, recombinant PTH, and raloxifene

News

Shoulder dystocia: Clarifying the care of an old problem

Author:: Steven R. Goldstein, MD

Publish date: October 1, 2007

Should maternal pushing stop once dystocia is diagnosed? Here’s light on the standard of care.

News

Does bone loss resume when alendronate is discontinued?

Author:: Steven R. Goldstein, MD

Publish date: March 1, 2007

News

Osteopenia: When to intervene?

Author:: Steven R. Goldstein, MD

Publish date: January 1, 2006

Why fracture risk assessment should rely on a constellation of factors—not just a numerical bone-density value

News

Preventing fragility fractures: Effective drugs and doses

Author:: Steven R. Goldstein, MD

Publish date: November 1, 2005

The latest data from well-designed trials, including FACT, CORE, and MOBILE, have enlightened us on efficacy, tolerability, and patient-friendly d...

News

Aromatase inhibitors and breast cancer? Don’t write off tamoxifen

Author:: Steven R. Goldstein, MD

Publish date: January 1, 2005

News

Reducing the risk of breast cancer: Key trials and their impact on practice

Author:: Steven R. Goldstein, MD

Publish date: July 1, 2003

An expert sifts the data regarding chemopreventive options and expands on current guidelines for endometrial cancer screening of tamoxifen users.<...